Journal of Neurology

, 254:1407 | Cite as

Substantia nigra hyperechogenicity correlates with clinical status and number of Parkin mutated alleles

  • J. M. Hagenah
  • I. R. König
  • B. Becker
  • R. Hilker
  • M. Kasten
  • K. Hedrich
  • P. P. Pramstaller
  • C. Klein
  • G. Seidel
ORIGINAL COMMUNICATION

Abstract

To further evaluate (1) transcranial sonography (TCS) for (pre)clinical diagnosis of Parkinson's disease (PD) and (2) to examine asymptomatic carriers of Parkin mutations we investigated substantia nigra (SN) hyperechogenicity in PD patients and unaffected subjects with and without Parkin mutations. The area (aSN) of the hyperechogenic SN were calculated bilaterally and study subjects were assigned to high versus low value groups. Eleven of the (affected and unaffected) mutation carriers had previously undergone 18-fluoro-dopa-(FDOPA)-PET scans. Fifty-eight individuals were investigated, including 24 with clinically definite and 34 without symptoms or signs of PD. Of the patients, three had one mutated and six had two mutated Parkin alleles. Of the unaffected subjects, 13 carried a single Parkin mutated allele. After dichotomization, 21 subjects had high and 37 subjects low values of mean aSN. Regarding the clinical status, 13 (62%) of the individuals with a high mean aSN had PD,while 26 (70%) of the study subjects with low values did not show signs of PD (p = 0.0393). Similarly, probands with high mean aSN values more frequently carried Parkin mutations (58%) than probands with low values (27%, p = 0.0234). A negative correlation between FDOPA uptake in the posterior putamen and maximum aSN was found in the group of mutation carriers (r = -.809, p = 0.0234). In conclusion, hyperechogenicity of the SN is found in both idiopathic and Parkin-associated PD. Further strengthening the notion of a potential relationship between SN hyperechogenicity and Parkin mutational status, a larger aSN was associated with an increasing number of mutated alleles in our study.

Key words

transcranial ultrasound Parkin mutations Parkinson's disease substantia nigra hyperechogenicity 

References

  1. 1.
    Becker G, Berg D (2001) Neuroimaging in basal ganglia disorder: perspectives for transcranial ultrasound. Mov Disord 16:23-2CrossRefPubMedGoogle Scholar
  2. 2.
    Behnke S, Berg D, Becker G (2003) Does ultrasound disclose a vulnerability factor for Parkinson's disease? J Neurol 250(Suppl 1):I24–I27CrossRefPubMedGoogle Scholar
  3. 3.
    Berg D, Becker G, Zeiler B, et al. (1999) Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 54:1026-031Google Scholar
  4. 4.
    Berg D, RoggendorfW, Schröder U, et al. (2002) Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 59:999-005CrossRefPubMedGoogle Scholar
  5. 5.
    Berg D, Schweitzer K, Leitner P, et al. (2005) Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease. Brain 128:3000-011PubMedGoogle Scholar
  6. 6.
    Berg D,Merz B, Reiners K,Naumann M, Becker G (2005) Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease. Mov Disord 20:383-85CrossRefPubMedGoogle Scholar
  7. 7.
    Braak H, Ghebremedhin E, Rüb U, Bratzke H, Tredici KD (2004) Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 318:121-34CrossRefPubMedGoogle Scholar
  8. 8.
    Buhmann C, Binkofski F,Klein C, et al. (2005) Motor reorganization in asymptomatic carriers of a single mutant Parkin allele: a human model for presymptomatic parkinsonism. Brain 128:2281-290CrossRefPubMedGoogle Scholar
  9. 9.
    Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 51:745-52CrossRefPubMedGoogle Scholar
  10. 10.
    Hagenah J,Hedrich K, Becker B, Pramstaller PP, Seidel G,Klein C (2006) Distinguishing early-onset PD from dopa-responsive dystonia with transcranial sonography. Neurology 66:759-61CrossRefGoogle Scholar
  11. 11.
    Hedrich K,Winkler S,Hagenah J, et al. (2006) Recurrent LRRK2 (PARK8) mutations in early-onset Parkinson's disease. Mov Disord 21:1506-510CrossRefPubMedGoogle Scholar
  12. 12.
    Hedrich K,Kann M, Lanthaler AJ, et al. (2001) The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism. Hum Mol Genet 10:1649-656CrossRefPubMedGoogle Scholar
  13. 13.
    Helmchen C, Schwekendiek A, Pramstaller PP, et al. (2006) Blink amplitude but not saccadic hypometria indicates carriers of Parkin mutations. J Neurol 253:1071-075CrossRefPubMedGoogle Scholar
  14. 14.
    Hilker R,Klein C, Ghaemi M, et al. (2001) Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene. Ann Neurol 49:367-76CrossRefPubMedGoogle Scholar
  15. 15.
    Khan NL, Scherfler C,Graham E, et al. (2005) Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation. Neurology 64:134-36PubMedGoogle Scholar
  16. 16.
    Klein C, Pramstaller PP, Kis B, et al. (2000) Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype. Ann Neurol 48:65-1CrossRefPubMedGoogle Scholar
  17. 17.
    Spiegel J,Hellwig D, Möllers M-C, et al. (2006) Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson’s disease. Brain 129:1188-193CrossRefPubMedGoogle Scholar
  18. 18.
    Walter U,Klein C,Hilker R, et al. (2004) Brain parenchyma sonography detects preclinical parkinsonism. Mov Disord 19:1445-449CrossRefPubMedGoogle Scholar
  19. 19.
    Zecca I, Berg D, Arzberger T, et al. (2005) In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Mov Disord 20:1278-285CrossRefPubMedGoogle Scholar

Copyright information

© Steinkopff-Verlag 2007

Authors and Affiliations

  • J. M. Hagenah
    • 1
  • I. R. König
    • 2
  • B. Becker
    • 1
  • R. Hilker
    • 4
  • M. Kasten
    • 1
  • K. Hedrich
    • 3
  • P. P. Pramstaller
    • 5
  • C. Klein
    • 1
  • G. Seidel
    • 1
  1. 1.Dept. of NeurologyUniversity of LübeckLübeckGermany
  2. 2.Institute of Medical Biometry and StatisticsUniversity of LübeckLübeckGermany
  3. 3.Dept. of Human GeneticsUniversity of LübeckLübeckGermany
  4. 4.Dept. of NeurologyUniversity of CologneCologneGermany
  5. 5.Dept. of NeurologyGeneral Regional Hospital Bolzano and Institute of Genetic Medicine, European Academy of BolzanoBolzanoItaly

Personalised recommendations